{"id":"NCT02507687","sponsor":"AbbVie","briefTitle":"Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension","officialTitle":"A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-27","primaryCompletion":"2021-11-24","completion":"2023-05-31","firstPosted":"2015-07-24","resultsPosted":"2024-05-10","lastUpdate":"2024-05-10"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Bimatoprost SR","otherNames":[]},{"type":"DRUG","name":"Sham Bimatoprost SR","otherNames":[]},{"type":"PROCEDURE","name":"Selective Laser Trabeculoplasty","otherNames":[]},{"type":"PROCEDURE","name":"Sham Selective Laser Trabeculoplasty","otherNames":[]}],"arms":[{"label":"Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye)","type":"EXPERIMENTAL"},{"label":"Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye)","type":"EXPERIMENTAL"},{"label":"Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye)","type":"EXPERIMENTAL"},{"label":"Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye)","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).","primaryOutcome":{"measure":"Change From Baseline in Intraocular Pressure at Week 4","timeFrame":"Baseline and Week 4","effectByArm":[{"arm":"Stage 2: SLT","deltaMin":-6.2,"sd":0.28},{"arm":"Stage 2: Bimatoprost SR 10 µg","deltaMin":-6.8,"sd":0.28}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0231"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":95,"countries":["United States","Australia","Canada","Denmark","France","Germany","Israel","New Zealand","Philippines","Poland","Russia","United Kingdom"]},"refs":{"pmids":["39800203","35943114"],"seeAlso":["https://www.abbvieclinicaltrials.com/study/?id=192024-093"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":56},"commonTop":["CONJUNCTIVAL HYPERAEMIA","INTRAOCULAR PRESSURE INCREASED","DRY EYE","PUNCTATE KERATITIS","VISUAL FIELD DEFECT"]}}